BDB102 / Seven and Eight BioPharma, Eikon Therap - LARVOL DELTA

Seven and Eight Biopharmaceuticals Announces Exclusive Clinical License Agreement with Eikon Therapeutics to Develop and Commercialize TLR7/8 dual agonists (Businesswire) - "Seven and Eight Biopharmaceuticals...announced today that it has signed an exclusive licensing agreement with Eikon Therapeutics. As part of the agreement, Eikon Therapeutics is awarded global rights to develop and commercialize the company’s novel immune modulator agonists targeting toll-like receptor 7 and 8 (TLR7/8)....The exclusive licensing agreement also includes development of novel Toll-like receptor ligand antibody conjugation (TLAC) molecules."

Licensing / partnership • Oncology • Solid Tumor